Develop and register acoziborole as a new, single-dose, oral treatment for T.b. gambiense sleeping sickness
current phase of drug development
updated 1 Mar 2022
In late 2009, acoziborole was selected as a pre-clinical candidate to treat sleeping sickness caused by T.b. gambiense. DNDi’s own lead optimization project led to the selection, starting with an initial hit identified in the Anacor chemical library. In 2012, acoziborole became the first new chemical entity to enter clinical development from DNDi’s own lead optimization programme.
The delivery of fexinidazole, a new all-oral treatment for Stage 1 and Stage 2 sleeping sickness, greatly improved therapeutic options for the disease. But the development of an additional oral drug, especially one that could be given as a one-day, single-dose treatment, could simplify administration and strengthen efforts towards sustained elimination of the disease.
Katey Owen, Director of Neglected Tropical Diseases, Bill & Melinda Gates Foundation
Fexinidazole is a true game-changer for sleeping sickness. If acoziborole, a single-dose treatment, is shown to be safe and effective, we’re hopeful it would provide national programmes an even better tool to help achieve global elimination goals.
News and publications
- 6 October 2021 – DNDi 2021 Projects of the Year recognize partners and colleagues for their work in developing new treatments for visceral leishmaniasis and sleeping sickness
- 4 September 2020 – Innovative single-dose oral sleeping sickness treatment to be co-developed by Sanofi and DNDi partnership
- 25 November 2019 – DNDi receives $29 million to fast-track the development of drugs to help eliminate sleeping sickness and river blindness
Get our latest news, personal stories, research articles, and job opportunities.